GlassScriptPhysician profile
Sean P Doran
NPI 1871911149
$877.65
in general payments reported to CMS, 2019-2025
13 companies · $333 in 2025
The $333 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $199 · 2022: $16.58 · 2023: $126 · 2024: $203 · 2025: $333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $627 · Education: $34.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $627.04 |
| Education | $34.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $502.06 | 2019-2025 | Skyrizi, Linzess, Creon |
| Janssen Biotech, INC. | $89.55 | 2024-2025 | Stelara, Tremfya |
| Phathom Pharmaceuticals, INC. | $62.10 | 2024 | Voquezna |
| Micro-Tech Endoscopy USA, INC. | $42.15 | 2024-2025 | Inflation Device, Biopsy Forceps |
| Ardelyx, INC. | $29.02 | 2025 | Ibsrela |
| Lilly USA, LLC | $27.19 | 2025 | Omvoh |
| Pfizer INC. | $23.49 | 2025 | |
| Celgene Corporation | $23.12 | 2023 | Zeposia |
| Fresenius Kabi USA, LLC | $20.90 | 2023 | |
| Genzyme Corporation | $20.77 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.03 | 2025 | Eohilia |
| Novo Nordisk INC | $18.27 | 2025 | Wegovy |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$17,623.22 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Doran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.